Clinicians who broaden their diagnostic criteria and consider GLP1s within a liverfirst strategy may improve outcomes for patients who would otherwise go untreated or underdiagnosed
However, if plateau seems premature, consider cycling your protocol
Within the past year, Dr Daniel Javitt has served as a consultant to Sepracor, AstraZeneca, Pfizer, Cypress Bioscience, Merck, Sunovion, Eli Lilly, and BMS, and has received research support from Pfizer, Roche, and Jazz Pharmaceuticals
Ann Saudi Med 2013;33:217-222
"Flat" Muscle Appearance : A loss of muscle fullness and glycogen storage, making the muscles look soft even as body fat drops
Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical Illness1